IDXX

IDEXX LaboratoriesA

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$718.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$596.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$480.00

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Recent news flow is earnings-positive, supported by reported growth and a modestly higher 2026 outlook. However, social coverage and analyst-revision data are unavailable, and no verified post-print market-reaction attribution is supplied; confidence is therefore below that of the primary operating evidence.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-04eventQ2 2026 results and higher FY2026 outlookMedium impact

IDEXX reported Q2 revenue growth of 10% reported and 9% organic, CAG Diagnostics recurring revenue growth of 11% reported and 10% organic, EPS of $4.27, and raised its 2026 EPS outlook to $14.69-$14.94 while narrowing revenue guidance to $4.700-$4.745 billion [#8-K-2026-08-04] [#SEC-8K-2026-08-04].

2026-12-31catalystRecurring diagnostics utilization and installed-base expansionHigh impact

Management cited volume-driven recurring diagnostics growth, innovation, and higher utilization; the IDEXX inVue Dx installed base surpassed 9,000 instruments after more than 1,600 quarterly placements [#8-K-2026-08-04].

2026-12-31catalystExecution against raised 2026 guidanceHigh impact

The raised midpoint incorporates stronger CAG Diagnostics recurring revenue performance despite a stated $15 million foreign-exchange headwind, creating a dated execution checkpoint through the remainder of 2026 [#8-K-2026-08-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology